Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

被引:2
|
作者
Liu, Tong [1 ]
Meng, Guorui [1 ]
Ma, Shihui [1 ]
You, Junqi [1 ]
Yu, Liang [1 ]
He, Risheng [1 ]
Zhao, Xudong [1 ]
Cui, Yunfu [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; tumor immune microenvironment; review; OPEN-LABEL; INFUSION CHEMOTHERAPY; PLUS; MULTICENTER; BEVACIZUMAB; SINTILIMAB; LENVATINIB; EFFICACY; THERAPY; SAFETY;
D O I
10.3389/fimmu.2024.1455716
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among primary liver cancers, hepatocellular carcinoma is the most common pathological type. Its onset is insidious, and most patients have no obvious discomfort in the early stage, so it is found late, and the opportunity for surgical radical treatment is lost, resulting in a poor prognosis. With the introduction of molecular-targeted drugs represented by sorafenib, patients with middle- and late-stage liver cancer have regained the light of day. However, their therapeutic efficacy is relatively low due to the limited target of drug action, toxic side effects, and other reasons. At this time, the emergence of immunotherapy represented by immune checkpoint inhibitors (ICIs) well breaks this embarrassing situation, which mainly achieves the anti-tumor purpose by improving the tumor immune microenvironment. Currently, ICI monotherapy, as well as combination therapy, has been widely used in the clinic, further prolonging the survival of patients with advanced hepatocellular carcinoma. This article reviews the development of monotherapy and combination therapy for ICIs in advanced hepatocellular carcinoma and the latest research progress.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma
    Pascale, Alina
    Allard, Marc Antoine
    Benamar, Amal
    Levy, Francis
    Adam, Rene
    Rosmorduc, Olivier
    JOURNAL OF HEPATOLOGY, 2024, 80 : S452 - S452
  • [32] The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma
    Wang, Yun
    Jiang, Man
    Zhu, Jingjuan
    Qu, Jialin
    Qin, Kang
    Zhao, Deze
    Wang, Li
    Dong, Lina
    Zhang, Xiaochun
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 132
  • [33] Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
    Shao, Yu-Yun
    Liu, Tsung-Hao
    Hsu, Chiun
    Lu, Li-Chun
    Shen, Yin-Chung
    Lin, Zhong-Zhe
    Cheng, Ann-Lii
    Hsu, Chih-Hung
    LIVER INTERNATIONAL, 2019, 39 (11) : 2184 - 2189
  • [34] Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
    Wu, Y. Linda
    van Hyfte, Grace
    Ozbek, Umut
    Reincke, Marlene
    Gampa, Anuhya
    Mohamed, Yehia I.
    Nishida, Naoshi
    Wietharn, Brooke
    Amara, Suneetha
    Lee, Pei-Chang
    Scheiner, Bernhard
    Balcar, Lorenz
    Pinter, Matthias
    Vogel, Arndt
    Weinmann, Arndt
    Saeed, Anwaar
    Pillai, Anjana
    Rimassa, Lorenza
    Naqash, Abdul Rafeh
    Muzaffar, Mahvish
    Huang, Yi-Hsiang
    Kaseb, Ahmed O.
    Kudo, Masatoshi
    Pinato, David J.
    Ang, Celina
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [35] Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma
    Pascale, Alina
    Allard, Marc Antoine
    Benamar, Amal
    Levi, Francis
    Adam, Rene
    Rosmorduc, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 457 - 457
  • [36] Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
    Wong, Jeffrey Sum Lung
    Kwok, Gerry Gin Wai
    Tang, Vikki
    Li, Bryan Cho Wing
    Leung, Roland
    Chiu, Joanne
    Ma, Ka Wing
    She, Wong Hoi
    Tsang, Josephine
    Lo, Chung Mau
    Cheung, Tan To
    Yau, Thomas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
  • [37] Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
    Abenavoli, Ludovico
    Montori, Michele
    Baroni, Gianluca Svegliati
    Argenziano, Maria Eva
    Giorgi, Francesca
    Scarlata, Giuseppe Guido Maria
    Ponziani, Francesca
    Scarpellini, Emidio
    MEDICINA-LITHUANIA, 2023, 59 (08):
  • [38] Immune checkpoint inhibitors for hepatocellular carcinoma-A game changer in treatment landscape
    Liu, Tsung-Hao
    Shen, Ying-Chun
    Cheng, Ann-Lii
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (08) : 1371 - 1383
  • [39] Combining Radioembolization and Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma: The Quest for Synergy
    Malone, Christopher D.
    Bajaj, Suryansh
    He, Aiwu
    Mody, Kabir
    Hickey, Ryan M.
    Sarwar, Ammar
    Krishnan, Sunil
    Patel, Tushar C.
    Toskich, Beau B.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2025, 36 (03)
  • [40] Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Han, Xinpu
    Sun, Qianhui
    Xu, Manman
    Zhu, Guanghui
    Gao, Ruike
    Ni, Baoyi
    Li, Jie
    SEMINARS IN LIVER DISEASE, 2023, 43 (04) : 383 - 401